- Home
- PGEN vs AYA Comparison
PGEN vs AYA Comparison
Compare PGEN & AYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | AYA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | PGEN | AYA |
|---|---|---|
| Price | $6.39 | $23.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $13.65 | ★ $31.88 |
| AVG Volume (30 Days) | ★ 4.6M | 780.9K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $2,365.68 | $112.24 |
| Revenue Next Year | $85.75 | $9.04 |
| P/E Ratio | $220.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.04 | $16.76 |
| 52 Week High | $8.98 | $30.67 |
Technical Indicators
Market Signals| Indicator | PGEN | AYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 36.14 |
| Support Level | $6.08 | $18.16 |
| Resistance Level | $7.44 | $30.44 |
| Average True Range (ATR) | 0.44 | 1.10 |
| MACD | -0.17 | -0.20 |
| Stochastic Oscillator | 2.37 | 3.33 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.